Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|September 7, 2021
Dr. Sarah Faris assesses tramadol and alternatives to opioid prescriptions
Author(s)Urology Times staff
“We have to be really careful prescribing tramadol and be aware that [it] can have really variable effects for patients,” says Sarah F. Faris, MD.
Advertisement
In this video, Sarah F. Faris, MD, discusses the risk of prescribing tramadol to patients and how her institution is currently developing ERAS pathways to minimize those prescriptions. Faris is an associate professor of surgery at the University of Chicago, Illinois.
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
Infertility care: Examining geographic gaps in access
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5